bioAffinity Technologies (BIAF) Competitors

AIkido Pharma (NASDAQ:AIKI) and bioAffinity Technologies (NASDAQ:BIAF) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, risk, analyst recommendations, earnings, community ranking, dividends and institutional ownership.

Is AIKI or BIAF more profitable?

AIkido Pharma has a net margin of 0.00% compared to AIkido Pharma's net margin of -313.34%. bioAffinity Technologies' return on equity of -18.21% beat AIkido Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AIkido Pharma	N/A	-18.21%	-16.94%
bioAffinity Technologies	-313.34%	-107.20%	-84.10%

Do institutionals and insiders believe in AIKI or BIAF?

10.9% of AIkido Pharma shares are owned by institutional investors. Comparatively, 1.6% of bioAffinity Technologies shares are owned by institutional investors. 8.6% of AIkido Pharma shares are owned by insiders. Comparatively, 36.4% of bioAffinity Technologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Which has better valuation & earnings, AIKI or BIAF?

AIkido Pharma has higher earnings, but lower revenue than bioAffinity Technologies. bioAffinity Technologies is trading at a lower price-to-earnings ratio than AIkido Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AIkido Pharma	$10K	1,146.37	-$7.17M	-$3.88	-0.54
bioAffinity Technologies	$2.53M	11.15	-$7.94M	-$0.90	-2.72

Which has more risk & volatility, AIKI or BIAF?

AIkido Pharma has a beta of 0.93, suggesting that its stock price is 7% less volatile than the S&P 500. Comparatively, bioAffinity Technologies has a beta of 3.15, suggesting that its stock price is 215% more volatile than the S&P 500.

Does the MarketBeat Community believe in AIKI or BIAF?

AIkido Pharma received 101 more outperform votes than bioAffinity Technologies when rated by MarketBeat users.

Company	Underperform	Outperform
AIkido Pharma	Outperform Votes 101 63.92%	Underperform Votes 57 36.08%
bioAffinity Technologies	N/A	N/A

Do analysts recommend AIKI or BIAF?

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AIkido Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A
bioAffinity Technologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A

Does the media prefer AIKI or BIAF?

In the previous week, bioAffinity Technologies had 4 more articles in the media than AIkido Pharma. MarketBeat recorded 5 mentions for bioAffinity Technologies and 1 mentions for AIkido Pharma. AIkido Pharma's average media sentiment score of 0.69 beat bioAffinity Technologies' score of 0.00 indicating that bioAffinity Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AIkido Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
bioAffinity Technologies	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

AIkido Pharma beats bioAffinity Technologies on 8 of the 14 factors compared between the two stocks.